on key Jim. are Today, launch. our priorities for thanks we three focused U.S. Great,
The an in in significant Journal the a our with ALS approved of data first a Medicine. clinical is for that England and publications trial effort peer-reviewed people and first includes This living awareness ALS survival clinical a as and educating as on the to RELYVRIO as as about demonstrate a drug well New publication function for to statistically benefit well drive clinicians. supporting RELYVRIO is benefit in sharing observed as analysis, post hoc on longer-term education such
work as goal towards who of priority is ensuring possible. and can eligible from treatment RELYVRIO quickly person second payers every engaging that Our as to efficiently has benefit our with access
that as clear process, The journey optimizing navigate facilitating Support best interactions enrolled This clinics with able have being ALS for process interactions in their third questions, to positive with RELYVRIO people ensuring the with an Amylyx. we ALS and is can. helping and the experience through field insurance program living Amylyx peoples Team includes people organized, treatment have positive Care
yield and of few we our of on a with approval priority people then. specific strong we September just in are on since States over There has let's observed first efforts XXXX, living areas. uptakes continued end Starting of ALS at each the focus results on the run FDA's with on XX. RELYVRIO have broad RELYVRIO, United were these through making details are of our rapid help the seeing Now awareness illustrate to uptake progress the XXXX ensuring and
a options. the growing our quarter continue believe to and believe we on ability treatment we of people this their basis. net our RELYVRIO to eager clinicians from new about we learn optimistic about are here are ALS remain end people of on and the roughly amount with We double as pace to try By on
half RELYVRIO encouraged the Prescribing prescriptions all XX is the coming side, the fairly approximately representing for of we during with key concentrated major was ALS at growth. and are from the On doctors significant ALS but centers, there prescriptions prescribers, ALS top opportunity clinician centers, roughly still quarter. mostly by
prescribers prescribers, of roughly With of regard we clinician the potential are XX believe RELYVRIO Out total these the clinicians prescribed XXX States. the roughly ALS in XXXX to top approximately market, there United by one patient. least From of healthcare thirds the top two perspective, to encouraging. quarter. numbers see fourth RELYVRIO of the the about these at office prescribed We as the ALS end centers have
have the As uptake opportunity we efforts, to education an see expand our deeper we key and broader providers. among
spectrum that are times we launch notable the when across people ALS diagnosis. of seeing at the part we the living look of with of Another initial is interest our
on people as important more people who We are have gaining are with who the In access been as other we seeing words, well that are years. since time diagnosed regardless ALS been and have in interested for this diagnosis, encouraged diagnosed treatment. new to of newly three others than RELYVRIO
priority, our vast of third people access Shifting through coverage approximately the formal policies lives More second representing U.S. gears RELYVRIO insurance this access to our insurers gained than covered point already the at had their broad one we to in anticipated RELYVRIO. have insurance to published and have majority coverage. launch. already provide
group. that country, of including policies them key plans, formalize the and half the their and players the this in commercial continue of first to included many across addition, year. majority We engaged In anticipate with early are we of the insurers this Medicare will remain during
people Support ensuring with therapy. between ALS, people RELYVRIO taking is have prescribed it ALS Moving have little enrollment on Amylyx and expeditiously RELYVRIO interactions, now programs, XX is clinics, get ACT Currently, form enrolled than as an priority been to our with of prescribed working who and living positive Care RELYVRIO team the us receiving our ALS to Team who third been also shipped. have in being and a known days living more
coverage speed this insurers process will formal implement up expect decisions. more as We
policies, period, plans exception/prior majority medical through is In RELYVRIO access while the this are their authorization to process. coverage interim the determining generally of
and approved approximately see to the patients ALS access on insurer. through requests have having success prior team Overall, our been submission pleased has been requirements. had their RELYVRIO have prescribed great most coverage XX% authorization despite helping gain first been have unique of that who with related people We
for were these In fourth of used the cases through quarter, our access roughly have the RELYVRIO our limited In XX% program and program insurer, where assistance programs. been patients. taking eligible we an of patient part people access granted interim hasn't
the with the most launch across and families. remains ALS the our approximately ALS in XXXX widespread Canadians Canada, and to importantly, Now entire Canada, with interest ecosystem turning in their ALBRIOZA living
of treatment by we seeing in and safety Mirroring encouraged to progression continue disease to ensure payers we of insurers the privately Canadians agreements equitable educate ALBRIOZA's private negotiated have possible. are the many to and pleased all to ALS eligible We access on XX% our what efficacy to Canadian efforts representing as and in cover with data ALBRIOZA are as uptake. largest broad are population. this we insured On approximately front, the Canadian U.S.,
and respect or public Pan-Canadian we funding, a Alliance of negotiations represents expected, provinces regards in breadth will in government PCPA, provide. to which scope as are the they coverage the With territories and to ongoing with Pharmaceutical
complete. typically the to have ALS equitable Canada's continue by As public for as at months insurance have up a and broad are private what advocate Amylyx, who XX reminder, process to access similar as to secured well to to covered takes will this to on large, the people we side. ALBRIOZA community options
timelines, elevated a does thus for we at half this to have lot now, an of XXXX. something a due expected limited is Time of more urgency. community Canada first process that to It's revenue important the of least anticipate note we have not in public through just opportunity and reimbursement sense
much are of I be proud done. very work team, by the more and progress but our our of to launches to We momentum date, our is am encouraged there and
every believe we benefit remains untapped for educating committed research ALS growth from conduct the outreach. additional of centers neurologist. treatment. as year, We person As who educate we look general with throughout to and ongoing our we to a opportunity support look can the driving and access eligible remain the forward large We to our with have team in efforts living rest ALS vigilant to
Justin the call updates for remarks. turn Josh I'll over and closing to With that, some and final
